ArticleCancer medicine journal2020

Burden of Proof: Evaluating the Efficacy of Tumor Mutational Burden (TMB) in Predicting Response to Immune Checkpoint Inhibitors.

James Newman et al.PubMed ↗Full text ↗

No numbers read from the abstract.